The checkpoint antibody, Tecentriq (atezolizumab), in combination with three other drugs, did not meet its primary endpoint of progression-free survival in a Phase 3 trial of women with advanced ovarian cancer, the developer Roche announced on 13 July. Tecentriq was being investigated with Avastin (bevacizumab), paclitaxel and carboplatin.
